Department of Urology, Nanjing Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
The Fourth Department of Infectious Disease, Huoshenshan Hospital, Wuhan, China.
Nephron. 2020;144(5):245-247. doi: 10.1159/000507261. Epub 2020 Mar 27.
Since December 2019, the epidemic of coronavirus disease 2019 (COVID-19) has spread very rapidly in China and worldwide. In this article, we report on a 75-year-old man infected with 2019 novel coronavirus who has end-stage kidney disease (ESKD). COVID-19 patients with ESKD need isolation dialysis, but most of them cannot be handled in time due to limited continuous renal replacement therapy (CRRT) machines. CRRT provided benefits for this patient by removing potentially damaging toxins and stabilizing his metabolic and hemodynamic status. With the control of uremia and fluid status, this patient ended up with an uneventful post-CRRT course, absence of clinical symptoms, and negative PCR tests. Greater efforts are needed to decrease the mortality of COVID-19-infected ESKD patients.
自 2019 年 12 月以来，2019 年冠状病毒病（COVID-19）疫情在中国和全球迅速蔓延。在本文中，我们报告了一名 75 岁的男子感染了 2019 年新型冠状病毒，他患有终末期肾病（ESKD）。COVID-19 合并 ESKD 的患者需要隔离透析，但由于连续肾脏替代治疗（CRRT）机器有限，大多数患者无法及时得到处理。CRRT 通过清除潜在的有害毒素并稳定其代谢和血液动力学状态，为该患者带来了益处。随着尿毒症和液体状态的控制，该患者在 CRRT 后没有出现并发症，没有临床症状，PCR 检测也呈阴性。需要付出更大的努力来降低 COVID-19 感染的 ESKD 患者的死亡率。
